Crohn's Disease - Thorne Research

ReviewCrohn’s Disease142. de Jong DJ, Goullet M, Naber TH. Side effectsof azathioprine in patients with Crohn’sdisease. Eur J Gastroenterol Hepatol2004;16:207-212.143. Gombar VK, Enslein K, Blake BW, EinsteinK. Carcinogenicity of azathioprine: an S-ARinvestigation. Mutat Res 1993;302:7-12.144. Goldstein ED, Marion JF, Present DH. 6-mercaptopurine is effective in Crohn’s diseasewithout concomitant steroids. Inflamm BowelDis 2004;10:79-84.145. Soon SY, Ansari A, Yaneza M, et al. Experiencewith the use of low-dose methotrexate forinflammatory bowel disease. Eur JGastroenterol Hepatol 2004;16:921-926.146. Drug Facts and Comparisons. 58 th ed. St.Louis, MO: Wolters Kluwer Health;2004:1898.147. Egan LJ, Sandborn WJ. Methotrexate forinflammatory bowel disease: pharmacologyand preliminary results. Mayo Clin Proc1996;71:69-80.148. Scribano M, Prantera C. Review article:medical treatment of moderate to severeCrohn’s disease. Aliment Pharmacol Ther2003;17:S23-S30.149. Ten Hove T, van Montfrans C, PeppelenboschMP, et al. Infliximab treatment inducesapoptosis of lamina propria T lymphocytes inCrohns’s disease. Gut 2002;50:206-211.150. Targan SR, Hanauer SB, Van Deventer SJ, etal. A short-term study of chimeric monoclonalantibody cA2 to tumor necrosis factor alphafor Crohn’s disease. N Engl J Med1997;337:1029-1035.151. Hanauer SB, Feagan BG, Lichtenstein GR, etal. Maintenance infliximab for Crohn’sdisease: the ACCENT I randomized trial.Lancet 2002;359:1541-1549.152. Cheifetz A, Smedley M, Martin S, et al. Theincidence and management of infusionreactions to infliximab: a large center experience.Am J Gastroenterol 2003;98:1315-1324.153. Keane J, Gerson S, Wise RP, et al. Tuberculosisassociated with infliximab, a tumornecrosis factor alpha neutralizing agent. NEngl J Med 2001;345:1098-1104.154. Colombel JF, Loftus EV Jr, Tremaine WJ, etal. The safety profile of infliximab in patientswith Crohn’s disease: the Mayo clinic experiencein 500 patients. Gastroenterology2004;126:19-31.155. Feagan BG, Sandborn WJ, Baker J, et al. Arandomized, double-blind, placebo-controlled,multi-center trial of the engineered humanantibody to TNF (CDP571) for steroid sparingand maintenance of remission in patients withsteroid-dependent Crohn’s disease. Gastroenterology2000;118:A655.156. Winter T, Wright J, Ghosh S, et al. IntravenousCDP870, a humanized anti-TNF antibodyfragment, in patients with active Crohn’sdisease – an exploratory study. Gastroenterology2003;124:A377.157. Rutgeerts P, Lemmens L, Van Assche G, et al.Treatment of active Crohn’s disease withonercept (recombinant human soluble p55tumour necrosis factor receptor): results of arandomized, open-label, pilot study. AlimentPharmacol Ther 2003;17:185-192.158. Sandborn WJ, Hanauer S, Loftus EV, et al. Anopen-label study of the human anti-TNFmonoclonal antibody adalimumab in subjectswith prior loss of response or intolerance toinfliximab for Crohn’s disease. Gastroenterology2004;126:A53-A54.159. Gordon FH, Lai CW, Hamilton MI, et al. Arandomized placebo-controlled trial of ahumanized monoclonal antibody to alpha4integrin in active Crohn’s disease. Gastroenterology2001;121:268-274.160. Rutgeerts P, Colombel J, Enns R, et al.Subanalyses from a phase 3 study on theevaluation of natalizumab in active Crohn’sdisease therapy-1(ENACT-1). Gut2003;52:Suppl VI:A239.161. Feagan BG, Greenberg G, Wild G, et al.Efficacy and safety of a humanizedalpha4beta7 antibody in active Crohn’sdisease. Gastroenterology 2003;124:A25-A26.162. Sandborn WJ, Faubion WA. Biologics ininflammatory bowel disease: how muchprogress have we made? Gut 2004;53:1366-1373.163. Kuroki F, Iida M, Tominaga M, et al. Multiplevitamin status in Crohn’s disease. Dig Dis Sci1993;38:1614-1618.164. Rath HC, Caesar I, Roth M, Scholmerich J.Nutritional deficiencies and complications inchronic inflammatory bowel disease. Med Klin1998;93:6-10. [Article in German]165. Geerling BJ, Badart-Smook A, StockbruggerRW, Brummer RJ. Comprehensive nutritionalstatus in patients with long-standing Crohndisease currently in remission. Am J Clin Nutr1998;67:919-926.Alternative Medicine Review ◆ Volume 9, Number 4 ◆ 2004 Page 395Copyright©2004 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission